1. Home
  2. LQDA vs AAMI Comparison

LQDA vs AAMI Comparison

Compare LQDA & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • AAMI
  • Stock Information
  • Founded
  • LQDA 2004
  • AAMI 1980
  • Country
  • LQDA United States
  • AAMI United States
  • Employees
  • LQDA N/A
  • AAMI N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • AAMI Investment Managers
  • Sector
  • LQDA Health Care
  • AAMI Finance
  • Exchange
  • LQDA Nasdaq
  • AAMI Nasdaq
  • Market Cap
  • LQDA 1.2B
  • AAMI 1.1B
  • IPO Year
  • LQDA 2018
  • AAMI N/A
  • Fundamental
  • Price
  • LQDA $19.60
  • AAMI $39.92
  • Analyst Decision
  • LQDA Strong Buy
  • AAMI Hold
  • Analyst Count
  • LQDA 9
  • AAMI 3
  • Target Price
  • LQDA $27.67
  • AAMI $30.33
  • AVG Volume (30 Days)
  • LQDA 2.4M
  • AAMI 278.3K
  • Earning Date
  • LQDA 08-06-2025
  • AAMI 07-31-2025
  • Dividend Yield
  • LQDA N/A
  • AAMI 0.10%
  • EPS Growth
  • LQDA N/A
  • AAMI 46.05
  • EPS
  • LQDA N/A
  • AAMI 2.40
  • Revenue
  • LQDA $14,144,000.00
  • AAMI $519,799,999.00
  • Revenue This Year
  • LQDA $189.27
  • AAMI $8.70
  • Revenue Next Year
  • LQDA $402.79
  • AAMI $7.69
  • P/E Ratio
  • LQDA N/A
  • AAMI $16.63
  • Revenue Growth
  • LQDA N/A
  • AAMI 18.00
  • 52 Week Low
  • LQDA $8.26
  • AAMI $21.49
  • 52 Week High
  • LQDA $19.76
  • AAMI $40.57
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 79.39
  • AAMI N/A
  • Support Level
  • LQDA $14.04
  • AAMI N/A
  • Resistance Level
  • LQDA $14.67
  • AAMI N/A
  • Average True Range (ATR)
  • LQDA 0.89
  • AAMI 0.00
  • MACD
  • LQDA 0.70
  • AAMI 0.00
  • Stochastic Oscillator
  • LQDA 97.88
  • AAMI 0.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About AAMI Acadian Asset Management Inc. Common Stock

Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.

Share on Social Networks: